COMMUNIQUÉS West-GlobeNewswire

Phenocell and Amarna Therapeutics Awarded Eurostars Grant to Assess a Gene Therapy for Dry AMD using a novel 3-dimensional iPSC-derived Retinal Model of the Disease
11/12/2024
Grasse, France and Leiden, the Netherlands – 11 December 2024 – Phenocell SAS (part of Axol Bioscience ) a leading provider of stem cell-derived models and services, and Amarna Therapeutics , a biotechnology pioneer in [...]
New Clinical Trial of eTNS for Pediatric ADHD to Commence at Denmark’s Center for Evidence-Based Psychiatry
11/12/2024
LOS ANGELES, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company, announced today that the Center for Evidence-Based Psychiatry (CEBP) in Denmark has approved commencing [...]
Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology
11/12/2024
KNOXVILLE, Tenn., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today the launch of VisiRose, Inc. (“VisiRose”), Provectus’s first Founded [...]
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital
11/12/2024
The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need. The clinical site is led by Brigham and Women’s Hospital researchers Ann Woolley, [...]
Gain Therapeutics To Present At Biotech Showcase 2025
11/12/2024
Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery Platform BETHESDA, Md., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical- [...]
Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference
11/12/2024
The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestones JERUSALEM, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or [...]
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
11/12/2024
Ness-Ziona, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Israeli Ministry [...]
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
11/12/2024
Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea’s experimental drug, ATRN-119, over a 24-hour daily cycle New regimen potentially optimizes [...]
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
11/12/2024
ANB032 was well tolerated across all doses with no safety signals observed AD trial and all further investment in ANB032 will be discontinued Anticipate top-line Phase 2b data in rheumatoid arthritis in February 2025 [...]
Genmab to Hold 2024 R&D Update and ASH Data Review Meeting
11/12/2024
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2024 – Genmab A/S (Nasdaq: GMAB) will hold its 2024 R&D Update and ASH Data Review Meeting [...]
Two Senior MEDIROM Mother Labs Executives Invest in Mother Labs’ Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000)
11/12/2024
TOKYO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”) announces that two senior executives, Issei Homan, Chief Technology Officer of MEDIROM MOTHER Labs [...]
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
10/12/2024
NAARDEN, The Netherlands and MIAMI, Dec. 10, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, [...]
Cellectis annonce le tirage de la troisième tranche de 5 millions d’euros dans le cadre du contrat de crédit conclu avec la Banque Européenne d’Investissement (BEI)
10/12/2024
NEW YORK , 10 déc. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS - NASDAQ : CLLS) (la "Société"), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome pour [...]
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
10/12/2024
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
10/12/2024
Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance Company continues focus on development of subcutaneous lonigutamab in thyroid eye disease, [...]
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024
10/12/2024
TUSTIN, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing [...]
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
10/12/2024
SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced the election of Mark S. Davis to its Board of Directors, effective [...]
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
10/12/2024
FOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today [...]
Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced
10/12/2024
Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpox Study stopped enrolling patients in all study arms Results affirm [...]

Pages